94 related articles for article (PubMed ID: 35720502)
1. Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation.
Kuwano A; Yada M; Narutomi F; Nagasawa S; Tanaka K; Kurosaka K; Ohishi Y; Masumoto A; Motomura K
Oncol Lett; 2022 Jul; 24(1):216. PubMed ID: 35720502
[TBL] [Abstract][Full Text] [Related]
2. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy.
Kudo M
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771637
[TBL] [Abstract][Full Text] [Related]
3. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
[TBL] [Abstract][Full Text] [Related]
5. Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
Cheon J; Jung S; Kim JS; Kang B; Kim H; Chan LL; Becker L; Gaillard VE; Chan SL; Kim C; Chon HJ
Liver Int; 2024 Apr; ():. PubMed ID: 38618972
[TBL] [Abstract][Full Text] [Related]
6. Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study.
Onuoha E; Smith AD; Cannon R; Khushman M; Kim H
J Gastrointest Cancer; 2023 Sep; 54(3):776-781. PubMed ID: 36030519
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma.
Inukai Y; Yamamoto K; Honda T; Yokoyama S; Ito T; Imai N; Ishizu Y; Nakamura M; Ishigami M; Kawashima H
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730627
[TBL] [Abstract][Full Text] [Related]
8. IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
Badhrinarayanan S; Cotter C; Zhu H; Lin YC; Kudo M; Li D
Future Oncol; 2024 Jun; ():1-9. PubMed ID: 38861301
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma.
Zanuso V; Pirozzi A; Balsano R; Pressiani T; Rimassa L
J Hepatocell Carcinoma; 2023; 10():1689-1708. PubMed ID: 37808223
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Kim TH; Kim BH; Cho YR; Koh YH; Park JW
J Liver Cancer; 2023 Sep; 23(2):330-340. PubMed ID: 37488926
[TBL] [Abstract][Full Text] [Related]
11. Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.
Sang YB; Lee C; Kim SG; Lee B; Kang B; Kim C; Chon HJ
J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592150
[No Abstract] [Full Text] [Related]
12. Elderly patient with unresectable advanced‑stage hepatocellular carcinoma who received atezolizumab plus bevacizumab and achieved a complete response: A case report.
Arima S; Kanda T; Totsuka M; Honda M; Kanezawa S; Sasaki-Tanaka R; Matsumoto N; Masuzaki R; Yamagami H; Ogawa M; Kogure H
Med Int (Lond); 2024; 4(3):23. PubMed ID: 38595809
[TBL] [Abstract][Full Text] [Related]
13. Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
Ishihara N; Komatsu S; Sofue K; Ueshima E; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Murakami T; Fukumoto T
Hepatol Res; 2024 Feb; ():. PubMed ID: 38353524
[TBL] [Abstract][Full Text] [Related]
14. A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma.
Kawanaka H; Tajiri K; Muraishi N; Murayama A; Nukui T; Yasuda I
Case Rep Gastroenterol; 2024; 18(1):8-13. PubMed ID: 38188593
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer.
Matsuda A; Ishiguro K; Yan IK; Patel T
Hepatol Commun; 2019 Apr; 3(4):525-541. PubMed ID: 30976743
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of immunotherapy in a rare subtype of hepatocellular carcinoma: a case report and literature review.
Archwamety A; Kunapinun N; Sirinvaravong S; Apisarnthanarak P; Akewanlop C; Korphaisarn K
Front Oncol; 2024; 14():1358804. PubMed ID: 38715785
[TBL] [Abstract][Full Text] [Related]
17. Stem Cell Growth Factor-β as a Predictive Biomarker of Response to Chemotherapy and Prognosis in Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Study.
Kimura M; Nishikawa K; Imamura J; Kimura K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254812
[TBL] [Abstract][Full Text] [Related]
18. Recommencement of atezolizumab with associated pulmonary sarcoid-like reaction.
Tam K; Wallace M; Mulrennan S
Respirol Case Rep; 2024 May; 12(5):e01363. PubMed ID: 38680668
[TBL] [Abstract][Full Text] [Related]
19. Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab".
Bae SH; Park HC
J Liver Cancer; 2023 Sep; 23(2):402-404. PubMed ID: 37680020
[No Abstract] [Full Text] [Related]
20. Pioneering applications of immunotherapy in the early stages of hepatocellular carcinoma.
Eleonora A; Nicola LE; Antonio NL; Massimo I
Dig Liver Dis; 2024 Jun; ():. PubMed ID: 38910073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
